A recent study demonstrated therapeutic effects of a new pimelic diphenylamide histone deacetylase (HDAC) inhibitor, HDACi 4b, in the R6/2 mouse model of Huntington’s disease (HD)1. This evidence concerns the gene HDAC9 and juvenile Huntington disease.